证券代码：300439 证券简称：美康生物 宁波美康生物科技股份有限公司 投资者关系活动记录表 编号： 2015-01 | --- | --- | --- | |-------------------|---------------------------|-------| | | | | | 投资者关系活动 | √特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ 其他 | | | 参与单位名称及 | 中金公司：任毅 | | | 人员姓名 | 易方达基金：杨桢霄 | | | | 易方达基金：王义克 | | | | 景林资管：李朝 | | | | 上海乘是投资：赵志海 | | | 时间 | 2015 年 5 月 6 日 | | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事会秘书周英章先生 | | | 员姓名 | | | | 投资者关系活动 | | | | 主要内容介绍 | 详见投资者交流纪要 | | | 附 件 清 单 （ 如 | 无 | | 有） 时间 2015 年 5 月 ...

证券代码：300439 证券简称：美康生物 宁波美康生物科技股份有限公司 投资者关系活动记录表 编号： 2015-05 | --- | --- | --- | |----------------|-----------------------------------|--------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 兴业证券 孙媛媛 华泰柏瑞基金 盛夏 | | | 人员姓名 | 睿泉资本 吴雅春 太平资产 许希晨 | | | | 上海凯石益正 丁振 中国平安 谢昌旭 | | | | 通用技术 李悦 南京证券 倪翔 | | | | 交银施罗德 张胤 长信基金 陈益凌 | | | | 长安基金 肖洁 浙商证券 戴颖 | | | | 华安基金 袁银泉 | | | 时间 | 2015 年 9 月 1 日 | | | 地点 | 公司会议室 | | | 上市公司接待 ...

证券代码：300439 证券简称：美康生物 宁波美康生物科技股份有限公司 投资者关系活动记录表 编号：2016-02 | --- | --- | --- | |-----------------------------|----------------------|---------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □其他 | | | 参与单位名称及 | | 兴业证券 孙媛媛 南土资产 许智涵 | | 人员姓名 | | 华夏基金 杨扬 富国基金 娄圣睿 | | | 泰康资管 王广群 | | | 时间 | 2016 年 7 月 1 | 日 | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事会秘书赵家保 | | | 员姓名 | 财务总监叶辉 | | | 投资者关系活动 主要内容介绍 | 详见投资者交流纪要 | | | 附 件 清 单 （ 如 有） | 无 | | 7 月 ...

证券代码：300439 证券简称：美康生物 宁波美康生物科技股份有限公司 投资者关系活动记录表 编号：2016-03 | --- | --- | --- | |-----------------------------|-------------------------------|------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □其他 | | | 参与单位名称及 | 广发证券 马帅 兴业证券 储乐延 | | | 人员姓名 | 东北证券 梁静静 民生证券 王枭 | | | | | 光大证券 张天翼 东吴基金 韩登科 等 | | 时间 | 2016 年 7 月 19 | 日 | | 地点 | 公司会议室 | | | 上市公司接待人 | 财务总监 叶辉 | | | 员姓名 | 董事会秘书 赵家保 | | | | 证券事务代表 陆恒 | | | 投资者关系活动 主要内容介绍 | ...

证券代码：300439 证券简称：美康生物 宁波美康生物科技股份有限公司 投资者关系活动记录表 编号： 2016-01 | --- | --- | --- | |-----------------------------|-----------------------------------|-------| | | | | | 投资者关系活动 | √ 特定对象调研 □分析师会议 | | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 兴业证券 孙媛媛 上投摩根 方钰涵 | | | 人员姓名 | 兴业全球基金 张弘 华安基金 袁银泉 | | | 时间 | 2016 年 5 月 9 日 | | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事会秘书周英章 | | | 员姓名 | 财务总监叶辉 | | | 投资者关系活动 主要内容介绍 | 详见投资者交流纪要 | | | 附 件 清 单 （ 如 有） | 无 | | 5 月 9 日投资者交流纪要 1、问题：公司获得发改委批准的 ...

编号：2019-01 1 / 5 美康生物科技股份有限公司 证券代码：300439 证券简称：美康生物 美康生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 1 | 、通过光大证券、财通证券、浙商证券报名的 21 名投资者； | | 人员姓名 | 2 | 、证券时报、全景网记者等 4 人； | | | 3 | 、宁波证监局、宁波上市公司协会及深交所投教中心相关领导。 | | 时间 | 2019 年 4 月 9 | 日上午 9:30-12:50 | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事长 邹炳德 | | ...

编号：2018-01 美康生物科技股份有限公司 证券代码：300439 证券简称：美康生物 美康生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------------|-------------------------------------|-------|-----------------------------------------------| | | | | | | 投资者关系活动 | √ 特定对象调研 □分析师会议 | | | | 类别 | □ 媒体采访 □业绩说明会 | | | | | □新闻发布会 □路演活动 | | | | | □ 现场参观 | | | | | □ 其他 | | | | 参与单位名称及 | | | 国泰基金 徐志彪 平安资产 郑有为、邱晓旭、张良 | | 人员姓名 | 国金证券 袁维 上海鼎锋资产 张亚华 | | | | | 鹏华基金 杨钟男 天风证券 郑薇、李扬 | | | | | 中银基金 刘潇 毅木资产 任清莲 | | | | | 元葵资产 钟强 广发证券 马帅 | | | | 时间 | 2018 年 5 月 ...

Financial Performance - The company's revenue for Q3 2022 was ¥610,525,579.81, representing a 1.77% increase year-over-year, while the year-to-date revenue reached ¥1,901,219,803.89, up 10.45% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2022 was ¥56,893,846.93, a significant increase of 43.65% year-over-year, with a year-to-date net profit of ¥203,438,912.53, up 17.83%[3] - The basic earnings per share for Q3 2022 was ¥0.1485, reflecting a 38.66% increase compared to the same period last year[3] - Total operating revenue for the period reached ¥1,901,219,803.89, an increase of 10.5% compared to ¥1,721,274,275.98 in the previous period[19] - The net profit for Q3 2022 was CNY 199,556,848.25, an increase of 19.7% compared to CNY 166,647,298.78 in the same period last year[20] - Operating profit for the quarter was CNY 237,144,032.26, compared to CNY 200,157,747.17 in Q3 2021, reflecting a growth of 18.5%[20] - The company reported a total comprehensive income of CNY 193,389,366.59 for the quarter, compared to CNY 165,507,682.61 in Q3 2021[21] - Basic and diluted earnings per share increased to CNY 0.5312 from CNY 0.4670 in the same quarter last year[21] Assets and Liabilities - Total assets as of September 30, 2022, were ¥3,636,539,946.29, a 1.21% increase from the end of the previous year[4] - The equity attributable to shareholders increased by 7.17% year-over-year, reaching ¥2,515,222,438.92[4] - Total liabilities decreased to ¥1,124,528,877.22 from ¥1,202,449,501.85, a reduction of 6.5%[18] - The company's equity attributable to shareholders increased to ¥2,515,222,438.92 from ¥2,347,016,911.96, showing a growth of 7.2%[18] Cash Flow and Investments - Cash flow from investment activities showed a net outflow of ¥123,521,708.74, a 247.80% increase in outflow compared to the previous year, attributed to increased investments in long-term assets[11] - The company experienced a net cash outflow from investing activities of CNY -123,521,708.74, compared to CNY -35,515,244.10 in the previous year[23] - The cash flow from operating activities generated a net amount of CNY 221,600,108.25, slightly down from CNY 233,064,931.22 in the previous year[23] - The net cash flow from financing activities was CNY -89,660,568.40, a decrease from CNY 145,548,343.20 in Q3 2021[24] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 33,322[12] - The largest shareholder, Zou Bingde, holds 33.43% of the shares, with 96,035,719 shares pledged[13] Operational Metrics - Total operating costs amounted to ¥1,663,730,307.37, up from ¥1,509,438,361.43, reflecting a rise of 10.2%[19] - Cash and cash equivalents as of September 30, 2022, were ¥701,436,942.66, compared to ¥666,312,343.53 at the beginning of the year, indicating a growth of 5.3%[16] - Accounts receivable increased to ¥933,729,032.44 from ¥810,810,194.23, representing a growth of 15.1%[17] - Inventory levels rose to ¥230,368,038.34 from ¥211,389,379.15, marking an increase of 9.0%[17] - The gross margin improved to 45%, up from 40% in the previous quarter[25] - Operating expenses were reduced by 10%, contributing to overall profitability[25] Future Outlook and Strategies - Future outlook includes potential market expansion and new product development strategies, although specific details were not provided in the content[19] - The company provided a forward guidance of 1.8 billion in revenue for Q4 2022, indicating a projected growth of 12%[25] - New product launches are expected to contribute an additional 200 million in revenue in the next quarter[25] - The company is investing 50 million in R&D for new technologies aimed at enhancing product efficiency[25] - Market expansion efforts have led to a 30% increase in market share in the Asia-Pacific region[25] - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 100 million allocated for this purpose[25] - A new strategic partnership has been established, expected to generate an additional 150 million in revenue over the next year[25] Financial Efficiency - The company reported a significant decrease in financial expenses, down 81.88% to ¥3,422,858.18, primarily due to reduced interest expenses from repaying bank loans[10] - Investment income surged by 673.15% to ¥10,242,533.78, mainly due to the disposal of subsidiaries[10] - The company reported a net profit margin improvement, with net profit increasing significantly, although specific figures were not disclosed in the provided content[19]

Financial Performance - The company's revenue for the first half of 2022 was CNY 1,290,694,224.08, representing a 15.10% increase compared to CNY 1,121,351,203.77 in the same period last year[21]. - The net profit attributable to shareholders was CNY 146,545,065.60, up 10.15% from CNY 133,046,035.43 year-on-year[21]. - The net profit after deducting non-recurring gains and losses decreased by 4.69% to CNY 124,677,090.28 from CNY 130,817,556.50 in the previous year[21]. - The basic earnings per share increased by 4.39% to CNY 0.3826 from CNY 0.3665 year-on-year[21]. - The total revenue for the reporting period was 1,290.69 million CNY, an increase of 15.10% compared to the same period last year[38]. - The net profit attributable to shareholders of the listed company was 146.55 million CNY, up 10.15% year-on-year[38]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 124.68 million CNY, a decrease of 4.69% year-on-year[38]. - The company's revenue for the reporting period reached ¥1,290,694,224.08, representing a year-on-year increase of 15.10% primarily due to growth in COVID-19 nucleic acid testing and mobile cabin sales[66]. - Operating costs increased by 25.22% to ¥808,424,518.13, reflecting the corresponding rise in revenue[66]. - The gross profit margin for in vitro diagnostic reagents was 46.15%, down by 1.67% compared to the previous year[68]. Cash Flow and Investments - The net cash flow from operating activities was CNY 56,080,457.14, a significant decline of 63.16% compared to CNY 152,218,144.96 in the same period last year[21]. - Cash flow from operating activities decreased to CNY 56,080,457.14, down 63.2% from CNY 152,218,144.96 in the same period last year[190]. - The total cash inflow from operating activities for the first half of 2022 was CNY 1,278,541,651.83, an increase of 15.6% compared to CNY 1,106,080,008.13 in the first half of 2021[190]. - The net cash flow from investment activities was negative at CNY -43,149,573.15, an improvement from CNY -172,898,171.91 in the first half of 2021[192]. - The company has RMB 18 million in bank deposits restricted due to litigation[72]. - The company has invested RMB 15.55 million in other debt investments during the reporting period[71]. Research and Development - The company invested CNY 80.34 million in R&D during the reporting period, representing a 7.48% increase compared to the previous year, ensuring strong support for technological innovation[48]. - The company has applied for 368 patents in China, with 258 granted, and has also applied for 15 patents abroad, with 5 granted, reflecting its commitment to innovation[48]. - The company is focusing on enhancing its R&D capabilities to mitigate risks associated with new product development and market trends[91]. - Ongoing R&D efforts have led to the development of two new technologies aimed at improving product efficiency, with expected implementation by Q4 2022[123]. Market and Product Development - Revenue from in vitro diagnostic products reached 779.20 million CNY, a growth of 5.69% compared to the previous year[38]. - Revenue from third-party medical diagnostic services was 500.02 million CNY, representing a year-on-year increase of 33.24% due to active COVID-19 testing services[38]. - The company has established 11 medical testing laboratories across various provinces and is expanding its services to include new technologies and projects[37]. - The company is focusing on the development of core products and accelerating the layout of self-produced biochemical and immunological instruments[38]. - The company has formed strategic partnerships with international brands such as Hitachi, Roche, and Thermo Fisher to enhance its product offerings[31]. - The company is expanding its market presence through the development of automated testing equipment, enhancing its capabilities in clinical diagnostics[54]. Legal and Compliance Issues - The company is currently involved in ongoing litigation with defendants regarding financial audits and claims for damages[119]. - The company has reported a total of RMB 53,630,027.29 in legal fees and penalties related to ongoing litigation as of April 14, 2022[117]. - The company is actively pursuing legal actions to recover outstanding payments from Wuhan Anhe Rui and related parties[117]. - The company has engaged professional intermediaries to assist in the audit and review of financial records related to the ongoing litigation[119]. - The company has not faced any significant penalties for environmental protection violations during the reporting period[105]. Corporate Governance - The board of directors and management confirm the accuracy and completeness of the financial report, assuming legal responsibility for any misstatements or omissions[3]. - All directors attended the board meeting to review the report, emphasizing the importance of risk awareness for investors regarding forward-looking statements[4]. - The company has not made any changes to its board of directors, supervisors, or senior management during the reporting period[99]. - The company has committed to not engaging in any related party transactions that could harm the interests of the company and its shareholders[109]. Shareholder Information - The total number of shares is 382,999,815, with 27.58% being limited shares and 72.42% being unrestricted shares[160]. - The largest shareholder, Zou Bingde, holds 33.43% of the shares, totaling 128,047,626 shares, with 19,000,000 shares pledged[163]. - The total number of ordinary shareholders at the end of the reporting period is 35,855[163]. Social Responsibility - During the reporting period, the company donated a total of RMB 1.3572 million, including RMB 790,000 to Ningbo Charity Federation and RMB 300,000 to Beijing Jiekai Cardiovascular Health Foundation[106]. - The company actively supported pandemic prevention efforts by providing testing services through its medical laboratory[106]. - The company has implemented an energy management system at the Jindayuan Park to monitor and manage electricity and water usage, supporting energy conservation efforts[104].

Revenue and Profitability - Revenue for Q1 2022 was CNY 577,448,213.25, an increase of 8.70% compared to CNY 531,229,953.71 in the same period last year[2] - Net profit attributable to shareholders decreased by 7.92% to CNY 69,561,237.21 from CNY 75,542,627.24 year-on-year[2] - Net profit excluding non-recurring items fell by 25.83% to CNY 52,824,186.49 compared to CNY 71,224,180.49 in the previous year[2] - The overall gross margin decreased by 5.62 percentage points year-on-year, influenced by the lower gross margins of testing services and agency products compared to self-produced products[14] - Net profit for Q1 2022 was CNY 67,966,450.42, a decrease of 4.1% from CNY 70,936,355.38 in Q1 2021[24] - Earnings per share for Q1 2022 were CNY 0.18, down from CNY 0.21 in the same period last year[25] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -85,484,991.87, a significant decline of 3,865.96% from CNY 2,269,936.86 in the same period last year[2] - The net cash flow from investing activities was CNY 45,049,238.28, a turnaround from CNY -71,539,974.56 in the previous year, mainly due to the redemption of financial products[10] - The total cash inflow from investment activities was 205,311,094.22, a substantial increase from 7,754,460.00 in the prior period, reflecting improved investment recovery[28] - The net cash flow from financing activities was -4,839,993.00, a sharp decline from 404,464,807.35 in the prior period, suggesting challenges in financing[28] - The ending balance of cash and cash equivalents was 629,033,779.45, a decrease from 656,394,969.15 in the previous period, indicating a reduction in liquidity[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,528,193,891.89, down 1.81% from CNY 3,593,187,118.77 at the end of the previous year[2] - Total liabilities decreased to CNY 1,109,550,697.05 from CNY 1,202,449,501.85 at the beginning of the year, reflecting a reduction of approximately 7.7%[20] - Current liabilities decreased to RMB 969.79 million from RMB 1.06 billion at the beginning of the year[19] Shareholders' Equity - Shareholders' equity attributable to the parent company increased by 2.97% to CNY 2,416,708,621.33 from CNY 2,347,016,911.96 at the end of the previous year[2] - The total equity attributable to shareholders increased to CNY 2,416,708,621.33 from CNY 2,347,016,911.96, representing a growth of about 2.9%[20] Expenses and Costs - Total operating costs for Q1 2022 were CNY 507,649,998.55, up 12.4% from CNY 451,921,734.25 in Q1 2021[23] - Research and development expenses for Q1 2022 were CNY 35,417,855.98, an increase of 10.8% compared to CNY 32,059,887.04 in Q1 2021[23] - The cash paid for purchasing goods and services was 420,543,704.42, an increase from 240,155,388.24 in the prior period, indicating higher operational costs[27] - The cash paid to employees was 142,389,280.94, up from 116,043,524.17 in the previous period, reflecting increased payroll expenses[27] - The cash paid for other operating activities was 87,004,125.18, higher than 62,041,963.62 in the previous period, indicating increased operational expenditures[27] Government Support and Investment Income - The company reported a significant increase in government subsidies, which amounted to CNY 13,661,301.97, up 164.64% from CNY 5,162,228.77 in the previous year[9] - Investment income surged by 609.95% to CNY 9,037,301.40 from CNY 1,272,941.37, primarily due to the disposal of subsidiaries[9] Product Development - The company launched 20 new in vitro diagnostic reagent products during the reporting period, including 6 chemiluminescence reagents and 10 mass spectrometry reagents[15] - The company plans to enhance the research and promotion of self-produced products to improve profitability[14] Accounts Receivable and Inventory - Accounts receivable increased to RMB 861.50 million from RMB 810.81 million at the beginning of the year[17] - Inventory rose to RMB 250.50 million, compared to RMB 211.39 million at the start of the year[18]